A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ACP-044 in Subjects With Pain Associated With Osteoarthritis of the Knee
Latest Information Update: 13 Oct 2022
At a glance
- Drugs CT 044 (Primary)
- Indications Osteoarthritis; Pain
- Focus Therapeutic Use
- Sponsors Acadia Pharmaceuticals
- 07 Oct 2022 Status changed from active, no longer recruiting to discontinued due to business reason.
- 30 Aug 2022 Status changed from recruiting to active, no longer recruiting.
- 18 Apr 2022 According to an Acadia Pharmaceuticals media release, this trial is expected to complete in the first half of 2023